GSK, a UK-based healthcare company, announced on Friday that it has commenced shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2021-22 flu season.
This move follows a licensing and lot-release approval from the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research.
The company is planning to distribute more doses than it has in any earlier influenza season, with a record supply of over 50 million doses of its influenza vaccine for the 2021-2022 season to the US market. Both FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT will be offered in 0.5mL, single-dose, pre-filled syringe, and indicated for patients six months and older in line with The US Centers for Disease Control and Prevention recommendations.
The World Health Organisation and FDA's Vaccines and Related Biological Products Advisory Committee recommended including A/Victoria/2570/2019 (H1N1) pdm09-like virus, A/Cambodia/e0826360/2020 (H3N2)-like virus, B/Washington/02/2019 (B/Victoria lineage)-like virus and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus for egg-based vaccines for the 2021-22 flu season.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial